Assessment of undiagonised anxiety and depression in patients attending teritiary care teaching hospital and role of clinical pharmacist in management

Authors

  • Uma Sankar Viriti Professor in Department of Pharmacy Practice, Avanthi Institute of Pharmaceutical Sciences, affiliated to JNTUGV, Cherukupally(V), Chittivalasa(M), Vizianagaram(Dist.) 531162
  • B.Kavya Sri Doctor of Pharmacy, Avanthi Institute of Pharmaceutical Sciences, affiliated to JNTUGV,Cherukupally(V), Chittivalasa(M), Vizianagaram(Dist.) 531162
  • C.Aruna Kumari Doctor of Pharmacy, Avanthi Institute of Pharmaceutical Sciences, affiliated to JNTUGV,Cherukupally(V), Chittivalasa(M), Vizianagaram(Dist.) 531162.
  • P.Sindhuja Doctor of Pharmacy, Avanthi Institute of Pharmaceutical Sciences, affiliated to JNTUGV,Cherukupally(V), Chittivalasa(M), Vizianagaram(Dist.) 531162.
  • P.Sowmya Doctor of Pharmacy, Avanthi Institute of Pharmaceutical Sciences, affiliated to JNTUGV,Cherukupally(V), Chittivalasa(M), Vizianagaram(Dist.) 531162.

DOI:

https://doi.org/10.47957/ijciar.v8i3.206

Keywords:

STAI (State Trait Anxiety Scale), BD-II (Beck Depression Inventory Scale), Anxiety, Depression, Anil Neerukonda Hospital

Abstract

Background:This research focuses on observing the mental health conditions of patients who are suffering from undiagnosed anxiety and depression attending tertiary care teaching hospital. We have evaluated and observed the number of participants of the study are being suffered and assessed the role of clinical pharmacist in identification and management.Methodology: The present study is a prospective observational analytical study involving 135 study participants who are having anxiety & depression but are being undiagnosed at tertiary care hospital Anil Neerukonda Hospital in Vizianagaram district. The Information was obtained through direct interaction with patients from different departments and they’re diagnosed using State Trait Anxiety Scale (STAI) and Beck Depression Inventory Scale (BD-II).Results:In the study, we reported a prevalence of 51% suffering from anxiety, 32% are suffering from depression and 17% are suffering from both anxiety and depression. Among these 13% of the study participants are of Low/No Depression, 6% with Moderate depression and 2% with Severe Depression. Whereas participants with anxiety were reported as 9% suffering with Low/No Anxiety, 12% with Moderate Anxiety and 0.7% suffering from High Anxiety Levels.Conclusion: Patients who are suffering from undiagnosed anxiety and depression are found to be experiencing trauma, stress and other psychological issues which affects their mental health condition.

Downloads

Download data is not yet available.

References

Mayo Clinic - Anxiety Definition and Symptoms: https://www.mayoclinic.org/diseases-conditions/anxiety/symptoms-causes/syc-20350961

"Anxiety Disorders Worldwide: Epidemiology and Trends" - PMC (2023). Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10862248/?

World Health Organization. (2017). Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: WHO. Retrieved from https://www.who.int/publications/i/item/depression-global-health-estimates

Mayo Clinic. (2023). Depression (major depressive disorder). Retrieved from: https://www.mayoclinic.org/diseases-conditions/depression/symptoms-causes/syc-20356007

Harvard Health Publishing. (2021). Types of Depression. Harvard Medical School. Retrieved from: https://www.health.harvard.edu/mind-and-mood/what-are-the-different-types-of-depression

Halbreich, U. (2017). Premenstrual Dysphoric Disorder (PMDD): Epidemiology and Treatment. National Institutes of Health. Retrieved from: https://pubmed.ncbi.nlm.nih.gov/28489360/

ullivan, P. F., Daly, M. J., & O'Donovan, M. (2018). Genetic architectures of psychiatric disorders: The emerging picture and its implications. The Lancet Psychiatry, 5(7), 583-596. DOI: https://doi.org/10.1016/S2215-0366(18)30102-0 DOI: https://doi.org/10.1016/S2215-0366(18)30102-0

World Health Organization (WHO). (2021). Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: WHO.

Momin & Rodrigues (Year). "The Prevalence of Undiagnosed Anxiety in the United States."

Mohamed, I. I., et al. (Year). "Anxiety and Depression in Substance Use Disorder Patients."

COPD Study (Year). "Prevalence of Anxiety and Depression in Chronic Obstructive Pulmonary Disease Patients."

van Beljouw, I. M. J. (2010). "The Course of Untreated Anxiety and Depression Over One Year."

Collins, B., et al. (Year). "The Impact of Undiagnosed Anxiety and Depression on Health and Social Care Costs."

Scott & Bisby (2022). "Meta-Analysis on the Untreated Progression of Anxiety Disorders."

Published

20-09-2025

How to Cite

Viriti, U. S., B, K. S., C, A. K., P, S., & P, S. (2025). Assessment of undiagonised anxiety and depression in patients attending teritiary care teaching hospital and role of clinical pharmacist in management. International Journal of Current Innovations in Advanced Research, 8(3), 1–13. https://doi.org/10.47957/ijciar.v8i3.206

Issue

Section

Original Articles

Citations